L’éducation de nos Enfants manipulée par le Lobby du Sucre

L’industrie du sucre va dire aux élèves ce qu’il faut manger pour être bonne santé!

Incroyable mais vrai: le Ministère de l’Education Nationale vient de nouer un partenariat avec l’industrie sucrière pour lui livrer la formation et l’information des enseignants et des élèves.

Ecoutez la chronique du Dr Dominique Dupagne sur France Inter le 6 février

Sources, BlogsArticles de Presse

Demandez l'annulation de l'accord CEDUS (lobby du sucre) / Education Nationale
Demandez l’annulation de l’accord CEDUS (lobby du sucre) / Education Nationale

Réagissez, signez la Pétition

We Are Giving Ourselves Cancer

RF Redberg cartoon, The NewYork Times, Jan 2014

We Are Giving Ourselves Cancer
Overused CT Scans are exposing Patients to Dangerous Levels of Radiation
by @RFRedberg @UCRadSafety

Sources:

On Flickr®

The Shocking True Difference between Organic and Natural

There are no standards or regulations for the labeling of natural food products if they do not contain meat or eggs…

“The False Advertising Industry” reveals the shocking truth about what is allowed in “Natural” food.  

More info and Videos

Distilbène : un scandale médical toujours d’actualité

Interview du Professeur Michel Tournaire, 2010

Novembre 2010: l’interview d’UniverScience TV du Professeur Michel Tournaire, membre du comité scientifique de l’association Réseau DES France.

  • Vidéo par universcience.tv, 22 Nov 2010.
  • Le 19 novembre 2010 se tenait au Sénat un colloque sur le Distilbène, ce médicament prescrit jusqu’en 1977 aux femmes ayant des problèmes de fécondité et qui a provoqué des cancers et malformations génitales chez leurs descendants. UniverScienceTV recevait le gynécologue Michel Tournaire, ancien chef de service de la maternité de l’hôpital Saint-Vincent-de-Paul à Paris.
Le Distilbène DES, en savoir plus

Safe and Dangerous: the FDA Says…

Natural News infographic, March 18, 2013

Safe and Dangerous: The FDA Says…, an #Infographics by @HealthRanger on Flickr
An infographic via @HealthRanger

Sources:

On Flickr®

Mammography Screening and Breast Cancer Incidence and Mortality

Mammography associated to breast cancer over-diagnosis with no significant reduction in mortality

“… in technically advanced countries, our results support the views of some commentators that the rationale for screening by mammography should be urgently reassessed by policy makers …”

Abstract

Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial
Too much mammography says @bmj_latest

Objective
To compare breast cancer incidence and mortality up to 25 years in women aged 40-59 who did or did not undergo mammography screening.

Design
Follow-up of randomised screening trial by centre coordinators, the study’s central office, and linkage to cancer registries and vital statistics databases.

Setting
15 screening centres in six Canadian provinces,1980-85 (Nova Scotia, Quebec, Ontario, Manitoba, Alberta, and British Columbia).

Participants
89 835 women, aged 40-59, randomly assigned to mammography (five annual mammography screens) or control (no mammography).

Interventions
Women aged 40-49 in the mammography arm and all women aged 50-59 in both arms received annual physical breast examinations. Women aged 40-49 in the control arm received a single examination followed by usual care in the community.

Main outcome measure
Deaths from breast cancer.

Results
During the five year screening period, 666 invasive breast cancers were diagnosed in the mammography arm (n=44 925 participants) and 524 in the controls (n=44 910), and of these, 180 women in the mammography arm and 171 women in the control arm died of breast cancer during the 25 year follow-up period. The overall hazard ratio for death from breast cancer diagnosed during the screening period associated with mammography was 1.05 (95% confidence interval 0.85 to 1.30). The findings for women aged 40-49 and 50-59 were almost identical. During the entire study period, 3250 women in the mammography arm and 3133 in the control arm had a diagnosis of breast cancer, and 500 and 505, respectively, died of breast cancer. Thus the cumulative mortality from breast cancer was similar between women in the mammography arm and in the control arm (hazard ratio 0.99, 95% confidence interval 0.88 to 1.12). After 15 years of follow-up a residual excess of 106 cancers was observed in the mammography arm, attributable to over-diagnosis.

Conclusion
Annual mammography in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available. Overall, 22% (106/484) of screen detected invasive breast cancers were over-diagnosed, representing one over-diagnosed breast cancer for every 424 women who received mammography screening in the trial.

Sources and Press releases:

Témoignage du Professeur Michel Tournaire sur les victimes du Distilbène DES

Michel Tournaire, comité scientifique de Réseau DES France, 2014

Février 2014: alors que nous attendons les résultats de l’Enquête Réseau DES France: Conséquences du #Distilbène pour trois Générations, voici le témoignage du Professeur Michel Tournaire, membre du comité scientifique de l’association Réseau DES France

Les résultats publiés

Le Distilbène DES, en savoir plus

Sponsored by “Drug You Like”

Doctors, drug companies and patients… Let the sunshine in

New efforts to reveal the ties between doctors and drug firms
Follow @TheEconomist for article updates, events and news from The Economist.

Sources:

On Flickr®

Farxiga FDA-approved Diabetes Drug that could increase the Risk of Cancer

The FDA has approved Farxiga drug to treat type 2 diabetes – but may in fact be linked to cancer…

The Worst New Drug of 2014?
FDA approves Farxiga to treat type 2 diabetes

” …it may seem early to be talking about one of the Food and Drug Administration’s (FDA’s) worst decisions of 2014…

The agency just approved a new diabetes medication that doesn’t noticeably improve health but may in fact be linked to cancer.

It’s called Farxiga (Dapagliflozin) and it will be available–and probably widely advertised–very soon…

Continue reading The Worst New Drug of 2014?
HuffPost Healthy Living, by Maria Rodale, 02/04/2014

Témoignage de Judith: ma vie avec le Distilbène

Vidéo par Réseau DES France, 2014

Judith, fille Distilbène, témoigne des effets subis du DES…

Le Distilbène DES, en savoir plus